awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q35968731-D76AFDE1-69AD-490E-8F32-A080FC7D6AEA
Q35968731-D76AFDE1-69AD-490E-8F32-A080FC7D6AEA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35968731-D76AFDE1-69AD-490E-8F32-A080FC7D6AEA
Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.
P2860
Q35968731-D76AFDE1-69AD-490E-8F32-A080FC7D6AEA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35968731-D76AFDE1-69AD-490E-8F32-A080FC7D6AEA
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4a030250f20ec8b9295c172cbf8fc7e174f0b1fe
P2860
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.